Theravance Biopharma Inc logo

TBPH

Theravance Biopharma Inc

$9.37

Earnings Summary

Revenue
$11.05Mn
Net Profits
$-8.19Mn
Net Profit Margins
-74.13%

Highlights

Revenue:

Theravance Biopharma Inc’s revenue fell -14.43% since last year same period to $11.05Mn in the Q2 2022. On a quarterly growth basis, Theravance Biopharma Inc has generated -16.26% fall in its revenue since last 3-months.

Net Profits:

Theravance Biopharma Inc’s net profit jumped 84.37% since last year same period to $-8.19Mn in the Q2 2022. On a quarterly growth basis, Theravance Biopharma Inc has generated 68.43% jump in its net profits since last 3-months.

Net Profit Margins:

Theravance Biopharma Inc’s net profit margin jumped 81.73% since last year same period to -74.13% in the Q2 2022. On a quarterly growth basis, Theravance Biopharma Inc has generated 62.3% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Theravance Biopharma Inc post its latest quarter earnings

EPS Estimate Current Quarter
0.11
EPS Estimate Current Year
0.11

Highlights

EPS Estimate Current Quarter:

Theravance Biopharma Inc’s earning per share (EPS) estimates for the current quarter stand at 0.11 - a 200% jump from last quarter’s estimates.

EPS Estimate Current Year:

Theravance Biopharma Inc’s earning per share (EPS) estimates for the current year stand at 0.11.

Key Ratios

Key ratios of the Theravance Biopharma Inc post its Q2 2022 earnings

Return on Assets (ROA)
-0.35
Return on Equity (ROE)
0
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Theravance Biopharma Inc’s return on assets (ROA) stands at -0.35.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Theravance Biopharma Inc’s return on equity (ROE) stands at 0.

Dividend Per Share (DPS):

Theravance Biopharma Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-06
-0.11
-0.34
-209.09%

Company Information

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. Its research is focused in the areas of inflammation and immunology.

Organisation
Theravance Biopharma Inc
Headquarters
George Town, Grand Cayman, Cayman Islands
Employees
359
Industry
Health Technology
CEO
Rick Winningham